Ventricular Assist Devices (VADs): Utilization, Management, and Clinical and Financial Outcomes
FRIDAY, SEPT. 12, 2014
Scott C. Silvestry, MD, Barnes-Jewish Hospital
Although heart transplants are considered the gold standard of treatment for advanced heart failure, the incidence of transplant is limited due to stringent selection criteria and the scarcity of acceptable donors. Because of this, VADs are showing trends of increasing utilization, expanding the previously limited scope of treatment options for patients with advanced heart failure.
While successful VAD implantation has many potential benefits it also carries risks and posttransplant case management is key for effective utilization. This session will discuss the complexity of patient management, patient selection, prior authorization, costs implications and outcomes.
- Discuss the benefits and risks of VAD implantation.
- Outline effect case management strategies post VAD implantation.
- Compare cost implications of poor versus effective management post VAD implantation and their outcomes.
These materials are intended ONLY for pharmacists and pharmacy technicians that attended the presentation, "Ventricular Assist Devices: Utilization, Management, and Clinical and Financial Outcomes" held at 12 p.m. Friday, Sept. 12, 2014. This session was part of the "23rd Annual National Conference" held in Chicago, Ill. on Sept. 10-12, 2014.
The prerequisite to this process is completing the 23rd Annual National Conference Post-Assessment and Evaluation. If there is a Prerequisite section above and the Status field is blank, click on '23rd Annual National Conference' to open the Assessment and Evaluation.
- 1.00 ACPE - Pharmacists